The relationship between platinum drug resistance and epithelial–mesenchymal transition (CROSBI ID 234584)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Brozović, Anamaria
engleski
The relationship between platinum drug resistance and epithelial–mesenchymal transition
One of the most commonly used chemotherapeutics, platinum drugs are used to treat a wide range of cancer types. Although many cancers initially respond well to those drugs, drug resistance occurs frequently and different molecular mechanisms have been associated with it. However, predictive biomarkers of cellular response in specific tumour types still do not exist. Epithelial– mesenchymal transition (EMT) is a malignant cancer phenotype characterised by aggressive invasion and metastasis, and resistance to apoptosis. Recent studies indicate that EMT accompanies the development of drug resistance to a number of cancer chemotherapies. The link between these two phenomena is still not elucidated, although several important molecules involved in both these complex processes, such as transcription factors (SNAIL, TWIST, ZEB, etc.) and miRNAs (miRNA-200 family, miR-15, miR- 186, etc.) have been recognised as important. This article reviews numerous unresolved issues regarding platinum drugs resistance and EMT, the complexity of the signalling networks that regulate those two phenomena and their importance in tumour response and spreading which are becoming focuses of interest of many scientists. This article also presents molecules involved in platinum resistance and EMT as possible targets for new cancer therapy.
Epithelial–mesenchymal transition ; Cisplatin ; Platinum drugs ; Drug resistance ; Tumour
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
91 (2)
2017.
605-619
objavljeno
0340-5761
1432-0738
10.1007/s00204-016-1912-7
Povezanost rada
Biologija, Temeljne medicinske znanosti